In a US study of 89 individuals with ER+ and/or PR+ breast cancer receiving AIs, only 34% of individuals with VMSs received some form of symptom-palliating treatment, reflecting a lack of appropriate care for this condition [30]. This evidence concerns the gene ESR1 and breast carcinoma.